9-氨基-2-羟基吖啶 | 7132-67-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 9-氨基-2-羟基吖啶
• 英文名称: 9-amino-acridin-2-ol
• 英文别名: 9-Amino-2-hydroxyacridine；9-aminoacridin-2-ol
• CAS: 7132-67-4
• 化学式: C₁₃H₁₀N₂O
• 分子量: 210.235
• InChiKey: IAPGOFICYOCHPX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  59.1
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为产物：
  描述：

  2-甲氧基吖啶-9-胺 在 水 、 氢溴酸 作用下， 反应 3.0h， 以86.9%的产率得到9-氨基-2-羟基吖啶
  参考文献：
  名称：

  Frameshift Mutagenicity and DNA Intercalation of 9-Amino-2-hydroxyacridine, a Rat Liver S9 Metabolite of 9-Aminoacridine

  摘要：

  合成了 9-氨基吖啶（9-AA）的大鼠肝脏 S9 代谢物--9-氨基-2-羟基吖啶，并发现它比 9-AA 具有更低的帧移诱变性和更强的 DNA 结合亲和力。

  DOI：

  10.1271/bbb.60.714

文献信息

• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• Synthesis of 9-amino-, 9-aminomethyl-1,2,3,4-tetrahydro- and 1,2,3,4,5,6,7,8-octahydroacridine derivatives
  作者：Maria Rosaria Del Giudice、Anna Borioni、Carlo Mustazza、Franco Gatta

  DOI：10.1002/jhet.5570340604

  日期：1997.11

  This paper describes the synthesis of 9-amino-2- and 4-hydroxy- and 2,4-dihydroxy-1,2,3,4-tetrahydro-acridines 2 and of 9-aminomethyl-1,2,3,4-tetrahydro- and 1,2,3,4,5,6,7,8-octahydroacridines 3 starting from the corresponding 9-carboxamido derivatives. A new synthetical pathway to 9-amino-2-hydroxyacri-dine 9 is also reported.

  本文描述了9-氨基-2-和4-羟基-和2,4-二羟基-1,2,3,4-四氢-啶2和9-氨基甲基-1,2,3,4-的合成从相应的9-羧酰胺基衍生物开始的四氢和1,2,3,4,5,6,7,8-八氢ac啶3。还报道了一种新的合成途径，可合成9-氨基-2-羟基a啶二酮9。
• Albert; Gledhill, Journal of the Society of Chemical Industry, 1945, vol. 64, p. 169,170
  作者：Albert、Gledhill

  DOI：——

  日期：——
• Compositions and methods for treatment of viral diseases
  申请人：Johansen Lisa M.

  公开号：US20080161324A1

  公开（公告）日：2008-07-03

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.
• NOVEL FLUORESCENCE DYES AND NOVEL ANALYTICAL PROCESSES FOR GLYCAN ANALYSIS
  申请人：ABBERIOR GMBH

  公开号：US20210373028A1

  公开（公告）日：2021-12-02

  The invention relates to a fluorescent marker according to the following formula I wherein Fluo is selected from the group consisting of substituted or non-substituted C10-C30 acridone, aminoacridine or pyrene, L is a linker and the moiety X is either a —SO 2 — or a —PO(OH)— moiety. Furthermore, the present invention relates to the use of the fluorescent markers of the invention, in particular also as a standard in glycan analysis, conjugates of fluorescent markers and glycans, as well as a kit-of-parts containing the fluorescent markers of the invention.